Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 6, 2005 - Issue 7
Submit an article Journal homepage
68
Views
0
CrossRef citations to date
0
Altmetric
Drug Evaluation

Clinical use of enoxaparin in the management of non-ST segment elevation acute coronary syndromes

John M Galla Duke Clinical Research Institute, Duke University Medical Center, 2400 Pratt Street, Durham, NC 27715, USA. [email protected]
&
Kenneth W Mahaffey Duke Clinical Research Institute, Duke University Medical Center, 2400 Pratt Street, Durham, NC 27715, USA. [email protected]
Pages 1241-1251 | Published online: 15 Jun 2005

Bibliography

  • FUSTER V, BADIMON L, BADIMON JJ,CHESBRO, JH: The pathogenesis of coronary artery disease and the acute coronary syndromes. N EngL J. Med (1992) 326:242–250.
  • ANTMAN EM, HANDIN R: Low-molecular-weight heparins: an intriguing new twist with profound implications. Circulation (1998) 98:287–289.
  • HARKER LA, HANSON SR,RUNGE MS: Thrombin hypothesis of thrombus generation and vascular lesion formation. Am. J. CardioL (1995) 75:12B–17B.
  • THE PURSUIT TRIALINVESTIGATORS: Inhibition of platelet glycoprotein IIb/Illa with eptifibatide in patients with acute coronary syndromes. N EngL J. Med. (1998) 339:436–443.
  • WEITZ JI: Low-molecular-weight heparins. N EngL J. Med. (1997) 337(10):688–698.
  • •• This article provides an excellent review of the LMNIVH class.
  • FAREED J, JESKE W,HOPPENSTEADT D, CLARIZIO R, WALENGA JM: Low-molecular-weight heparins: pharmacologic profile and product differentiation. Am. J. Cardiol 82 (5B):3L–10L.
  • HANSEN JB, SANDSET PM: Differential effects of low molecular weight heparin and unfractionated heparin on circulating levels of antithrombin and tissue factor pathway inhibitor (TFPI): a possible mechanism for difference in therapeutic efficacy. Thromb. Res. (1998) 91:177–181.
  • MONTALESCOT G, PHILIPPE G, ANKRI A et al.: Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease: Beneficial effects of enoxaparin. Circulation (1998) 98:294–299.
  • BROZE GR: The tissue factor pathway of coagulation. In: Thrombosis and Hemorrhage. J Loscalzo, Al Shafer (Eds), Blackwell Scientific Publications, Boston, MA, USA (1994):57–86.
  • YOUNG E, PRINS, LEVINE MN, HIRSH J: Heparin binding to plasma proteins, an important mechanism for heparin resistance. Thromb. Haemost. (1992) 67(6):539–543.
  • YOUNG E, WELLS P, HOLLOWAY S, WEITZ J, HISRH J: Ex-vivo and in-vitro evidence that low molecular-weight heparins exhibit less binding to plasma proteins than unfractionated heparin. Thromb. Haemost. (1994) 71(3):300–304.
  • ABBATE R, GORI AM, FARSI A et al: Monitoring of low-molecular-weight heparins in cardiovascular disease. Am. J. Cardiol (1998) 82 (5B):33L–36L
  • SANDERINK GJ, LE LIBOUX A, JARIWALA J et al.: The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers. Clin. Pharmacol Ther. (2002) 72(3):308–318.
  • VAN WIJK EM, SMIT JL: A chromogenic micro-assay for factor-X activity. Thromb. Res. (1984) 34(3):263–268.
  • KEREIAKES DJ, MONTALESCOT G, ANTMAN EM et al: Low-molecular-weight heparin therapy for non-ST-elevation acute coronary syndromes and during percutaneous coronary intervention: an expert consensus. Am. Heart J. (2002) 144(4):615–624.
  • •This consensus paper outlines the safety and efficacy of enoxaparin in the treatment of NSTE ACS.
  • BECKER RA, SPENCER FA, GIBSON M et al: Influence of patient characteristics and renal function on Factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes. Am. Heart J. (2002) 143:753–759.
  • MARTIN J, FRY E, SANDERINK G, ATHERLEY et al: Reliable anticoagulation with enoxaparin in patients undergoing percutaneous coronary intervention: the pharmacokinetics of enoxaparin in PCI (PEPCI) study. Cath. Cardiovasc. Intervent (2004) 61:163–170.
  • ••This trial evaluated enoxaparin dosing forNSTE ACS patients who undergo percutaneous coronary intervention.
  • COLLET JP, MONTALESCOT G, LISON L et al: Percutaneous coronary intervention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris. Circulation (2001) 103:658–663.
  • ANTMAN EM, MCCABE CH, GURFINKEL et al: Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction: results of the Thrombolysis In Myocardial Infarction (TIMI) 11B trial. Circulation (1999) 100: 1593-1601.
  • NARINS CR, HILLEGASS WB Jr, NELSON CL et al: Relation between activated clotting time during angioplasty and abrupt closure. Circulation (1996) 93(4):667–671.
  • MOLITERNO DJ, HERMILLER JB, KEREIAKES DJ et al.: A novel point-of-care enoxaparin monitor for use during percutaneous coronary intervention: results of the Evaluating Enoxaparin Clotting Times (ELECT) study./ Am. Coll Cardiol (2003) 42:1132–1139.
  • SAW J, DEREIAKES DJ,MAHAFFEY KW et ell.: Evaluation of a novel point-of-care enoxaparin monitor with central laboratory anti-Xa levels. Thromb. Res. (2003) 112:301–306.
  • HANDELAND GF, ABILDGAARD U, HOLM HA, ARNESEN KE: Dose adjusted heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin. Eur. J. Clin. Pharmacol (1990) 39(2):107–112.
  • BARA L, BILLAUD E, GRAMOND G, KHER A. SAIVIAMA M: Comparative pharmacokinetics of a low molecular weight heparin (PK 10169) and unfractionatedheparin after intravenous and subcutaneous administration. Thromb. Res. (1985) 39(5):631–636.
  • BARA L, SAMAMA M: Pharmacokinetics of low molecular weight heparins. Acta Chir. Scand. (1988) 543:65–72.
  • COHEN M, DEMERS C,GURFINKEL EP et al: A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl. J. Med. (1997) 337(7):447–452.
  • ••This was the first randomised trial ofenoxaparin versus UFH in NSTE ACS patients.
  • COHEN M, THEROUX P, BORZAK S et al: Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: the ACUTE II study. Am. Heart J. (2002) 144:470–477.
  • GOODMAN SG, FITCHETT D, ARMSTRONG PW et al: Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/Illa inhibitor eptifibatide. Circulation (2003) 107:238–244.
  • THE SYNERGY TRIALINVESIGATORS: Enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. J. Am. Med. Assoc. (2004) 292:45–54.
  • ••This study encorporated updatedtreatment algorithms and is the largest to compare enoxaparin to UFH in NSTE ACS.
  • BLAZING MA, DE LEMOS JA, WHITE HD et al: Safety and efficacy of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial. J. Am. Med. Assoc. (2004) 292:55–64.
  • PETERSEN JL, MAHAFFEY KW, HASSELBLAD Vet al: Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-segment elevation acute coronary syndromes: a systematic overview. J. Am. Med. Assoc. (2004) 292:89–96.
  • ••This is the pooled analysis of the six randomised trials and provides a comprehensive review of the use of enoxaparin in the management of NSTE ACS.
  • GOODMAN SG, COHEN M,BIGNOZI F et al.: Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: one-year results of the ESSENCE study. J. Am. Coll. CardioL (2000) 36(3):693–698.
  • ANTMAN EM, COHEN M, RADLEY D et al.: Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction: TIMI 11B-ESSENCE meta-analysis. Circulation (1999) 100: 1602-1608.
  • KEREIAKES DJ, GRINES C, FRY E et al.:Enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary intervention. J. Invas. CardioL (2001) 13:272–278.
  • THE EPILOG INVESTIGATORS: Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N EngL J. Med. (1997) 336:1689–16896.
  • THE EPISENT INVESTIGATORS: Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/Illa blockade. Lancet (1998) 352:87–92.
  • FERGUSON JJ, ANTMAN EM, BATES ER et al.: Combining enoxaparin and glycoprotein IIb/Illa antagonists for the treatment of acute coronary syndromes: Final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study. Am. Heart J. (2003) 146:628–634.
  • SUGIYAMA T, ITOH M, OHTAWA M, NATSUGA T: Study on neutralization of low molecular weight heparin (LMWH) by protamine sulfate and its neutralization characteristics. Thromb. Res. (1992) 68(2):119–129.
  • FAREED J, HOPPENSTEADT D, WALENGA J et al.: Pharmacodynamic and pharmacokinetic properties of enoxaparin: Implications for clinical practice.Clin. Pharmacokinet. (2003) 42(12):1043–1057.
  • RACINE E: Differentiation of the low-molecular-weight heparins. Pharmacotherapy (2001) 21(6 Pt 2):625–705.
  • MICHALIS LK, KATSOURAS CS, PAPAMICHAEL N et al.: Enoxaparin versus tinzaparin in non-ST-segment elevation acute coronary syndromes: the EVET trial. Am. Heart J. (2003) 146:304–310.
  • WHITE HD, KLEIMAN NS, CHEW D et al.: Efficacy and safety of percutaneous coronary intervention in acute coronary syndrome patients randomized to enoxaparin or unfractionated heparin: results of SYNERGY. J Am. Coll. Cardiol. (2005) (Abstract).

Websites

  • http://www.acc.org/clinical/guidelines/ unstablefincorporated/index.htm ACC/AHA 2002 Guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.